Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856432 | 0.97 | ALOX5 (0.61) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL8561986 | 0.96 | KMT2A (0.55) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL27747363 | 0.93 | KMT2A (0.53) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL9051523 | 0.93 | NPC1 (0.61) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL2003642 | 0.90 | KMT2A (0.53) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL417705 | 0.89 | MAPT (0.60) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL2825416 | 0.88 | MAPT (0.69) | KMT2ASLC6A2SLC6A3TDP1HTT | |
| SCHEMBL4626752 | 0.88 | KMT2A (0.50) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL523154 | 0.86 | KMT2A (0.67) | KMT2ASLC6A2SLC6A3TDP1ALOX5 | |
| SCHEMBL6282770 | 0.85 | KMT2A (0.81) | KMT2ASLC6A2SLC6A3TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1531904-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| WO-2004007024-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006913-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-0763026-B1 | GASTRIN AND CCK ANTAGONISTS | BLACK JAMES FOUNDATION (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-5939437-A | AMIDE COMPOUNDS AS NEUROPEPTIDES AS APPETITE REGULATORS, ANXIOLYTIC ACTIVITY AND ANTICARCINOGENIC AGENTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-08-17 | — | — | US | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5912260-A | GASTRIC ACID SECRETION | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-06-15 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| EP-0763026-A1 | GASTRIN AND CCK ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0719251-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| WO-1995032949-A1 | GASTRIN AND CCK ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995030647-A1 | CCK AND GASTRIN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995005359-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | KMT2A 3382/4885SLC6A2 575/4885SLC6A3 94/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | KMT2A 2962/4885SLC6A2 3807/4885SLC6A3 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.